New pill aims to boost platelets in hard-to-treat ITP patients
NCT ID NCT07196163
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests an experimental drug called golidocitinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The trial includes 138 participants who have not responded well to standard treatments. The goal is to see if the drug can safely raise platelet counts to safer levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
Conditions
Explore the condition pages connected to this study.